Clarus Therapeutics Holdings, Inc. (CRXT): Price and Financial Metrics
GET POWR RATINGS... FREE!
CRXT Stock Price Chart Interactive Chart >
CRXT Price/Volume Stats
|Current price||$0.05||52-week high||$10.57|
|Prev. close||$0.07||52-week low||$0.05|
|Day high||$0.07||Avg. volume||6,391,756|
|50-day MA||$0.29||Dividend yield||N/A|
|200-day MA||$1.30||Market Cap||2.47M|
Clarus Therapeutics Holdings, Inc. (CRXT) Company Bio
Clarus Therapeutics Holdings, Inc. operates as a men's health specialty pharmaceutical company that focuses on the development and commercialization of oral testosterone replacement therapy in the United States. It offers JATENZO, a soft gel oral formulation of testosterone undecanoate for treating hypogonadal men. The company has a licensing agreement with HavaH Therapeutics for product to treat androgen-dependent inflammatory breast disease and certain forms of breast cancer. Clarus Therapeutics Holdings, Inc. was founded in 2003 and is based in Northbrook, Illinois.
Most Popular Stories View All
CRXT Latest News Stream
|Loading, please wait...|
CRXT Latest Social Stream
View Full CRXT Social Stream
Latest CRXT News From Around the Web
Below are the latest news stories about CLARUS THERAPEUTICS HOLDINGS INC that investors may wish to consider to help them evaluate CRXT as an investment opportunity.
It's time for another breakdown of the biggest pre-market stock movers as we go over the latest news on Tuesday morning.
Fans of AMC Entertainment (AMC) stock will want to keep an eye on the company come Sept. 3 as it prepares for a special theater event.
Humanigen (HGEN) stock is heading lower on Monday as investors react to a minimum price delisting notice from the Nasdaq Exchange.
Pinduoduo (PDD) stock is getting a boost on Monday after the Chinese agriculture tech company released results for Q2 2022.
Clarus Therapeutics (CRXT) stock is falling hard on Monday as investors prepare for the stock to be delisted later this week.
CRXT Price Returns